Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Nelfinavir and Bortezomib in Advanced Hematologic Malignancies

NCT01164709 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT01164709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01164709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Nelfinavir and Bortezomib in Advanced Hematologic Malignancies
Lead sponsor
Swiss Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2010
Completion date
November 30, 2013
Enrollment
18 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma, mature t-cell and nk-cell neoplasms, multiple myeloma and plasma cell neoplasm